PMID:
World J Gastroenterol. 2019 Oct 21 ;25(39):6025-6040. PMID: 31660038
Abstract Title:
Allicin as add-on therapy forinfection: A systematic review and meta-analysis.
Abstract:
BACKGROUND: Allicin (2-propene-1-sulfinothioic acid S-2-propenyl ester, diallyl thiosulfinate) extracted from garlic, has proven activity against() infection. In recent years, clinical trials have explored its utility as an add-on therapy with variable outcomes reported.AIM: To perform a systemic review of allicin as an add-on treatment forinfection and assess its efficacy in randomized controlled trials (RCTs).METHODS: Electronic databases including MEDLINE, EMBASE, the Web of Science, the Cochrane Database, the China National Knowledge Infrastructure Database, Chinese VIP Information Databases, Chinese Medical Databases, and the Wan-Fang Database were searched for keywords including"allicin","","randomized clinical trials", and their synonyms. A meta-analysis was performed using the fixed-effects model for low heterogeneity and the random-effects model for high heterogeneity with sensitivity analysis. Bias was evaluated using Egger's tests. Trial sequential analysis (TSA) was used to evaluate information size and treatment benefits. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to assess the level of quality, and studies were classed as"high quality","moderate quality","low quality", and"very low quality".RESULTS: A total of eight RCTs consisting of 867 participants (435 from the allicin group and 432 from the control group) were included. Eradication rate in the allicin group (93.33%, 406/435) was significantly higher than that of the control group (83.56%, 361/432) [= 0%, odds ratio (OR) = 2.75, 95% confidence interval (CI): 1.74-4.35,
Health Time 